DANBURY, Conn., July 24, 2013 (GLOBE NEWSWIRE) -- ATMI, Inc. (Nasdaq: ATMI ), a global technology company, today reported revenues and net income for the second quarter of 2013.
Revenues were $102.0 million during the second quarter of 2013, compared with $105.9 million during the same period last year. Net income was $9.4 million, or $0.29 per diluted share, compared with $11.4 million, or $0.35 per diluted share, during the second quarter of 2012.
"Our second quarter results reflect a mixed demand environment in Microelectronics and continued momentum in LifeSciences, resulting in revenues that are up sequentially but lower than last year," said Chief Executive Officer Doug Neugold. "Within Microelectronics, we view the market as generally tepid. Leading edge foundries continue to be strong, while there were meaningful wafer start declines in the logic space, which impact certain of our product lines. LifeSciences achieved record revenue due to growth across most product lines as the business continues to benefit from the adoption of single-use technology. We continued to make progress on commercializing our electronic waste recovery solution, eVOLV™ by signing another agreement during the quarter, our first in Asia."
Second quarter operating income was $12.7 million compared with $16.9 million during the same period last year as the benefit from lower operating expense was offset by lower gross profit due to lower sales volume and a less favorable product mix.
During the second quarter ATMI recognized $0.6 million of license revenues related to eVOLV. "Interest in our sustainable solution to electronic waste recovery is very high, and we anticipate additional license revenues during the next several quarters from pending license agreements, and subsequent royalty revenues contributing to results in a meaningful way beginning in late 2014," added Neugold.
Second Quarter 2013 Segment Results
Microelectronics
- Revenues were $89.4 million, up 1 percent sequentially, but down 5 percent compared with last year
- Strong demand from certain customers tied to the global market for mobile devices was offset by a decline in logic at some key accounts, along with ongoing pressure from customers' material efficiency gains
- Operating income was $26.9 million, down 11 percent as lower operating expenses were offset by lower gross profit
LifeSciences
- Revenues were $11.9 million, up 7 percent compared with last year
- Continued demand for single-use products drove the improvement, with strong growth in equipment
- Operating loss of $1.7 million compared with a loss of $1.1 million last year
Market Environment
"With growing uncertainty around consumer electronic demand trends, the outlook for wafer starts is being tempered as we look into the second half of the year," commented Neugold. "Our expectation now is for minimal wafer start growth in 2013. While we still see momentum for advanced devices used in mobile applications, there is growing evidence that other segments are not as strong. We continue to work to overcome these challenges by maintaining our focus on the leading edge. LifeSciences is growing in line with our expectations and is steadily marching toward our target of 20 to 30 percent annual growth, and achieving breakeven performance during the fourth quarter of 2013. Finally, I'm very pleased with our success in eVOLV and anticipate this business will become more meaningful to our financial results over the next several quarters."
Webcast Information
A conference call (dial-in: 877.766.0748) discussing the Company's financial results and business outlook will begin at 11:00 a.m. Eastern time, July 24, 2013. A replay of the call will be available for 48 hours at 855.859.2056 (access code 93696366). The call can also be accessed live and on-demand from the ATMI Investor Relations website at http://investor.atmi.com . A copy of management's presentation materials will be available on the ATMI Investor Relations website before the call.
About ATMI
ATMI, Inc. is a global provider of specialty semiconductor materials, and safe, high-purity materials handling and delivery solutions designed to increase process efficiencies for the microelectronics, life sciences, and other industries. For more information, please visit http://www.atmi.com .
ATMI, eVOLV, and the ATMI logo are trademarks or registered trademarks of Advanced Technology Materials, Inc., in the United States, other countries, or both.
Forward Looking Statements
Statements contained herein that relate to ATMI's future performance, including, without limitation, statements with respect to ATMI's anticipated results of operations or level of business for 2013 or any other future period, are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations only and are subject to certain risks, uncertainties, and assumptions, including, but not limited to, changes in semiconductor and life sciences industry growth (including, without limitation, wafer starts) or ATMI's markets; competition, problems, or delays developing, commercializing, and delivering new products; customer-driven pricing pressure; potential loss of key customers; problems or delays in integrating acquired operations and businesses; uncertainty in the credit and financial markets; ability to protect ATMI's proprietary technology; and other factors described in ATMI's Form 10-K for the year ended December 31, 2012 and other subsequent filings with the Securities and Exchange Commission. Such risks and uncertainties may cause actual results to differ materially from those expressed in our forward-looking statements. ATMI undertakes no obligation to update any forward-looking statements.
| ATMI, INC. | ||||
| SUMMARY STATEMENTS OF COMPREHENSIVE INCOME | ||||
| (in thousands, except per share data) | ||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||
| 2013 | 2012 | 2013 | 2012 | |
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | |
| Revenues | $ 102,008 | $ 105,899 | 201,415 | 198,473 |
| Cost of revenues | 53,351 | 52,425 | 106,071 | 100,817 |
| Gross profit | 48,657 | 53,474 | 95,344 | 97,656 |
| Operating expenses: | ||||
| Research and development | 13,130 | 13,825 | 26,312 | 28,314 |
| Selling, general and administrative | 22,812 | 22,713 | 45,980 | 46,259 |
| Total operating expenses | 35,942 | 36,538 | 72,292 | 74,573 |
| Operating income | 12,715 | 16,936 | 23,052 | 23,083 |
| Interest income | 302 | 305 | 656 | 630 |
| Other income (expense), net | 1,247 | (457) | 1,620 | (763) |
| Income before income taxes | 14,264 | 16,784 | 25,328 | 22,950 |
| Provision for income taxes | 4,817 | 5,361 | 7,455 | 7,665 |
| Net income | $ 9,447 | $ 11,423 | 17,873 | 15,285 |
| Earnings per diluted share | $ 0.29 | $ 0.35 | $ 0.55 | $ 0.47 |
| Weighted average shares outstanding - diluted | 32,739 | 32,669 | 32,737 | 32,683 |
| Comprehensive income | $ 1,207 | $ 13,083 | 7,755 | 13,320 |
| ATMI, INC. | ||
| SUMMARY BALANCE SHEETS | ||
| (in thousands) | ||
| June 30, 2013 (Unaudited) | December 31, 2012 | |
| Assets | ||
| Cash & marketable securities (1) | $114,583 | $156,447 |
| Accounts receivable, net | 69,905 | 60,806 |
| Inventories, net | 94,907 | 87,555 |
| Other current assets | 38,969 | 25,736 |
| Total current assets | 318,364 | 330,544 |
| Property, plant, and equipment, net | 134,876 | 125,099 |
| Marketable securities, non-current (1) | 10,001 | 12,073 |
| Other assets | 121,921 | 131,437 |
| Total assets | $585,162 | $599,153 |
| Liabilities and stockholders' equity | ||
| Accounts payable | $33,855 | $38,573 |
| Other current liabilities | 26,287 | 36,329 |
| Total current liabilities | 60,142 | 74,902 |
| Non-current liabilities | 14,535 | 16,975 |
| Stockholders' equity | 510,485 | 507,276 |
| Total liabilities & stockholders' equity | $585,162 | $599,153 |
| (1) Total cash and marketable securities equaled $124.6 million and $168.5 million at June 30, 2013 and December 31, 2012, respectively. | ||
| ATMI, INC. | ||||
| Segment Results | ||||
| (in thousands) | ||||
| (Unaudited) | ||||
| Revenue | ||||
| Three Months Ended | Six Months Ended | |||
| June 30, | June 30, | |||
| 2013 | 2012 | 2013 | 2012 | |
| Microelectronics | $ 89,414 | $ 94,518 | $ 177,525 | $ 177,983 |
| LifeSciences | 11,944 | 11,154 | 23,225 | 20,263 |
| All Other | 650 | 227 | 665 | 227 |
| Total Consolidated | $ 102,008 | $ 105,899 | $ 201,415 | $ 198,473 |
| Operating income (loss) | ||||
| Three Months Ended | Six Months Ended | |||
| June 30, | June 30, | |||
| 2013 | 2012 | 2013 | 2012 | |
| Microelectronics | $ 26,926 | $ 30,397 | $ 52,168 | $ 51,429 |
| LifeSciences | (1,682) | (1,104) | (2,940) | (3,230) |
| All Other | (12,529) | (12,357) | (26,176) | (25,116) |
| Total Consolidated | $ 12,715 | $ 16,936 | $ 23,052 | $ 23,083 |
Troy Dewar Director, Investor Relations and Corporate Communications 203.207.9349
